bioAffinity Technologies (BIAF) wins approval for major equity plan, offerings and reverse split
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
bioAffinity Technologies, Inc. reported results of its 2026 Annual Meeting, where stockholders approved several equity and capital structure proposals. They expanded the 2024 Equity Incentive Compensation Plan to reserve 1,000,000 shares, up from 66,666, increasing capacity for stock-based awards. Holders also approved issuances tied to August 2025 warrants and Series B preferred stock, including anti-dilution adjustments that could add hundreds of thousands of shares upon exercise or conversion. Stockholders authorized potential non-public offerings that may trigger a change of control under Nasdaq rules and approved a discretionary 1‑for‑2 to 1‑for‑250 reverse stock split, which the board may implement or abandon. All six director nominees were elected and the independent auditor was ratified.
Positive
- None.
Negative
- Stockholders approved multiple dilution-related items, including increasing the 2024 equity plan reserve to 1,000,000 shares, warrant and preferred stock anti-dilution adjustments, and authorizations for non-public offerings that may significantly expand the share count.
- A broad 1-for-2 to 1-for-250 reverse stock split was approved, giving the board wide discretion to alter the share structure, which can affect liquidity and perceived value.
Insights
Shareholders approved substantial equity issuance flexibility and a wide reverse split range.
Stockholders authorized a sharp increase in the 2024 equity plan pool to 1,000,000 shares from 66,666 and backed multiple warrant and preferred stock anti-dilution adjustments, potentially adding up to several hundred thousand shares upon exercise or conversion. These actions expand tools for compensation and financing but also increase potential dilution relative to the existing share base.
They also cleared non‑public offerings and any related change in control under Nasdaq Marketplace Rule 5635(d), and approved a reverse stock split in a 1‑for‑2 to 1‑for‑250 range, at the board’s discretion. Future board decisions on offering size, pricing, and whether to execute a split will shape the actual impact on shareholders.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares outstanding record date: 4,498,675 shares
Equity plan reserve: 1,000,000 shares
Prior equity plan reserve: 66,666 shares
+5 more
8 metrics
Shares outstanding record date
4,498,675 shares
Common stock issued and outstanding as of March 13, 2026 record date
Equity plan reserve
1,000,000 shares
New 2024 Equity Incentive Compensation Plan share reserve
Prior equity plan reserve
66,666 shares
Previous 2024 Equity Incentive Compensation Plan share reserve
August 2025 warrant shares
271,500 shares
Common stock issuable upon exercise of August 2025 warrants
Max shares after warrant anti-dilution
365,620 shares
Aggregate maximum issuable under August 2025 warrant anti-dilution provision
Series B anti-dilution shares
131,884 shares
Common stock issuable upon conversion of Series B Preferred Stock after anti-dilution
Reverse split range
1-for-2 to 1-for-250
Board-authorized reverse stock split ratio range
Votes for reverse split
1,211,478 votes
Votes for Proposal 9 reverse stock split approval
Key Terms
anti-dilution provision, Series B Preferred Stock, Nasdaq Marketplace Rule 5635(d), reverse stock split, +1 more
5 terms
anti-dilution provision financial
"The stockholders approved an anti-dilution provision of the August 2025 Warrants and the reduction in the exercise price"
Series B Preferred Stock financial
"The stockholders approved an anti-dilution provision of the Series B Preferred Stock and the reduction in the exercise price"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Nasdaq Marketplace Rule 5635(d) regulatory
"The stockholders authorized the issuance of securities in one or more non-public offerings in accordance with Nasdaq Marketplace Rule 5635(d)"
reverse stock split financial
"to effect a reverse stock split with respect to the Company’s issued and outstanding shares of Common Stock"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
warrant inducement transaction financial
"warrants issued in connection with the warrant inducement transaction that closed on August 14, 2025"
A warrant inducement transaction is when a company issues warrants—options to buy shares at a set price—as a sweetener to persuade investors or creditors to approve a deal, restructuring, or other corporate action. Think of it like giving coupons to convince people to agree to a plan; it can speed approvals but may dilute existing shareholders and change potential future share value, so investors watch these carefully.
FAQ
What key proposals did bioAffinity Technologies (BIAF) stockholders approve at the 2026 Annual Meeting?
Stockholders approved director elections, auditor ratification, a major increase in the 2024 equity plan share reserve, warrant and preferred stock anti-dilution adjustments, authorization for certain non-public offerings, and a discretionary 1-for-2 to 1-for-250 reverse stock split.
How did bioAffinity Technologies (BIAF) change its 2024 Equity Incentive Compensation Plan?
The 2024 Equity Incentive Compensation Plan was amended to increase shares of common stock reserved for issuance to 1,000,000 from 66,666. This significantly expands capacity for future stock-based awards to employees, directors, and other eligible participants under the plan.
What did bioAffinity Technologies (BIAF) approve regarding August 2025 warrants?
Stockholders approved issuance of up to 271,500 common shares upon exercise of August 2025 warrants and an anti-dilution adjustment that can increase that to a maximum of 365,620 shares, reflecting lower exercise prices subject to stated per-share floor prices under the warrant terms.
What is the Series B Preferred Stock anti-dilution adjustment for bioAffinity Technologies (BIAF)?
Stockholders approved an anti-dilution provision for Series B Preferred Stock that reduces its conversion price, subject to a $3.00 per share floor, and allows issuance of up to 131,884 common shares upon conversion if the anti-dilution mechanism is fully triggered.
What reverse stock split authority did bioAffinity Technologies (BIAF) receive?
Stockholders approved an amendment allowing the board, at its discretion, to implement a reverse stock split between 1-for-2 and 1-for-250, covering issued, outstanding, and treasury shares. The board may select the exact ratio in a later public announcement or abandon the split.
Did bioAffinity Technologies (BIAF) stockholders approve potential non-public offerings and related control changes?
Yes. Stockholders authorized issuance of securities in one or more non-public offerings under Nasdaq Marketplace Rule 5635(d) and approved any resulting change in control, giving the company flexibility to raise capital through privately negotiated transactions if pursued.